Literature DB >> 23676502

CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.

Ye Chen1, Rodrigo Jacamo, Marina Konopleva, Ramiro Garzon, Carlo Croce, Michael Andreeff.   

Abstract

We examined the role of microRNAs (miRNAs) in targeting the stromal-derived factor 1α/CXCR4 (SDF-1α/CXCR4) axis to overcome chemoresistance of AML cells. Microarray analysis of OCI-AML3 cells revealed that the miRNA let-7a was downregulated by SDF-1α-mediated CXCR4 activation and increased by CXCR4 inhibition. Overexpression of let-7a in AML cell lines was associated with decreased c-Myc and BCL-XL protein expression and enhanced chemosensitivity, both in vitro and in vivo. We identified the transcription factor Yin Yang 1 (YY1) as a link between SDF-1α/CXCR4 signaling and let-7a, as YY1 was upregulated by SDF-1α and downregulated by treatment with a CXCR4 antagonist. ChIP assay confirmed the binding of YY1 to unprocessed let-7a DNA fragments, and treatment with YY1 shRNA increased let-7a expression. In primary human AML samples, high CXCR4 expression was associated with low let-7a levels. Xenografts of primary human AML cells engineered to overexpress let-7a exhibited enhanced sensitivity to cytarabine, resulting in greatly extended survival of immunodeficient mice. Based on these data, we propose that CXCR4 induces chemoresistance by downregulating let-7a to promote YY1-mediated transcriptional activation of MYC and BCLXL in AML cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676502      PMCID: PMC3668829          DOI: 10.1172/JCI66553

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  Cancer genomics: small RNAs with big impacts.

Authors:  Paul S Meltzer
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

3.  CXCR4 is a prognostic marker in acute myelogenous leukemia.

Authors:  Anke C Spoo; Michael Lübbert; William G Wierda; Jan A Burger
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

4.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.

Authors:  Dorothy A Sipkins; Xunbin Wei; Juwell W Wu; Judith M Runnels; Daniel Côté; Terry K Means; Andrew D Luster; David T Scadden; Charles P Lin
Journal:  Nature       Date:  2005-06-16       Impact factor: 49.962

5.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

6.  miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Authors:  Ann-Kathrin Eisfeld; Guido Marcucci; Kati Maharry; Sebastian Schwind; Michael D Radmacher; Deedra Nicolet; Heiko Becker; Krzysztof Mrózek; Susan P Whitman; Klaus H Metzeler; Jason H Mendler; Yue-Zhong Wu; Sandya Liyanarachchi; Ravi Patel; Maria R Baer; Bayard L Powell; Thomas H Carter; Joseph O Moore; Jonathan E Kolitz; Meir Wetzler; Michael A Caligiuri; Richard A Larson; Stephan M Tanner; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

Review 7.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.

Authors:  S Gordon; G Akopyan; H Garban; B Bonavida
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

Review 8.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

9.  Let-7 expression defines two differentiation stages of cancer.

Authors:  Scott Shell; Sun-Mi Park; Amir Reza Radjabi; Robert Schickel; Emily O Kistner; David A Jewell; Christine Feig; Ernst Lengyel; Marcus E Peter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-28       Impact factor: 11.205

10.  MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.

Authors:  R Garzon; F Pichiorri; T Palumbo; M Visentini; R Aqeilan; A Cimmino; H Wang; H Sun; S Volinia; H Alder; G A Calin; C-G Liu; M Andreeff; C M Croce
Journal:  Oncogene       Date:  2007-01-29       Impact factor: 9.867

View more
  88 in total

Review 1.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

2.  Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.

Authors:  Zhi-hua Yu; Te Liu; Yan-hui Zhao; Yong-yi Huang; Yong-tao Gao
Journal:  Tumour Biol       Date:  2014-01-10

Review 3.  Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

Authors:  Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann
Journal:  Biochim Biophys Acta       Date:  2015-03-27

4.  Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

Authors:  Byung-Sik Cho; Zhihong Zeng; Hong Mu; Zhiqiang Wang; Sergej Konoplev; Teresa McQueen; Marina Protopopova; Jorge Cortes; Joseph R Marszalek; Sheng-Bin Peng; Wencai Ma; R Eric Davis; Donald E Thornton; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

Review 5.  Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Authors:  Nijiro Nohata; Yusuke Goto; J Silvio Gutkind
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

6.  Roadblocks to translational advances on metastasis research.

Authors:  Thomas Brabletz; David Lyden; Patricia S Steeg; Zena Werb
Journal:  Nat Med       Date:  2013-09       Impact factor: 53.440

7.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 8.  Targeting the microenvironment in acute myeloid leukemia.

Authors:  Armin Rashidi; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

9.  Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.

Authors:  J Huan; N I Hornick; N A Goloviznina; A N Kamimae-Lanning; L L David; P A Wilmarth; T Mori; J R Chevillet; A Narla; C T Roberts; M M Loriaux; B H Chang; P Kurre
Journal:  Leukemia       Date:  2015-06-25       Impact factor: 11.528

10.  Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Authors:  Tibor J Kovacsovics; Alice Mims; Mohamed E Salama; Jeremy Pantin; Narayanam Rao; Ken M Kosak; Peter Ahorukomeye; Martha J Glenn; Michael W N Deininger; Kenneth M Boucher; Linda M Bavisotto; Gerardo Gutierrez-Sanchez; Thomas P Kennedy; Stephen G Marcus; Paul J Shami
Journal:  Blood Adv       Date:  2018-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.